



## Curriculum Vitae

### Personal information

First name(s) / Surname(s) **Fulvio Magni**  
 Address(es) University of Milano-Bicocca; Department of Medicine and Surgery  
 Telephone(s) +390264488213 Mobile: +393394165079  
 E-mail Fulvio.magni@unimib.it  
 Nationality Italian  
 Date of birth 13/08/1957  
 Gender Male

### Occupational field

#### Work experience

Date From April 2016  
 Occupation or position held **Full Professor on Biochemistry**  
 Name and address of employer University of Milano-Bicocca, Department of Medicine and Surgery [www.unimib.it](http://www.unimib.it)  
 Type of business or sector University - Research

Date July 2002 - 2016  
 Occupation or position held **Associate Professor on Biochemistry**  
 Name and address of employer University of Milano-Bicocca, Department of Medicine and Surgery [www.unimib.it](http://www.unimib.it)  
 Type of business or sector University - Research

Dates 1988 - 2002  
 Occupation or position held **Senior researcher**  
 Name and address of employer IRCC San Raffaele  
 Type of business or sector R&D -

### Personal skills and competences

Mother tongue(s) **Italian**

Other language(s) **English**

Self-assessment

*European level (\*)*

**Language**

Understanding		Speaking		Writing	
Listening	Reading	Spoken interaction	Spoken production		
C1	C1	C1	C1	C1	

(\*) [Common European Framework of Reference for Languages](#)

**Editorial activity and Commission of Trust**

**Editorial Activity:** Associate Editor of “Journal of Integrated OMICS: a methodological journal” and of “Journal of Analytical, Bioanalytical and Separation Techniques”.

**Commission of Trust**

2009 Expert referee for the evaluation of research proposals area.1.2 "Detection, Diagnosis and Monitoring" under the call FP7-HEALTH-2009-two-stage.

2012-2013 Expert referee for the evaluation of research; FIRB, PRIN, Futuro in Ricerca, Ministero Istruzione Università Ricerca (MIUR), Italy

2010-Present Expert referee for the evaluation for ANVUR - VQR. Agenzia Nazionale di Valutazione del Sistema Universitario e della Ricerca - Valutazione della Qualità della Ricerca, Ministero Istruzione Università Ricerca (MIUR), Italy

**Grant referee** for: MIUR; PRIN; Regione Calabria, ANVUR; French National Cancer Institute; Futura Giovani; National Science Centre Poland; Novo Nordisk Foundation; .

**Referee for peer reviewed scientific journals:** Referees for several International Scientific Journals. Among them: Proteomics, Proteomics J.– Clinical Application, Expert Review in Proteomics, Clinical biochemistry, Cancer Research, Molecular Biosystem, PlosOne, Journal of Cancer Research and Clinical Oncology, FEBS, J of Proteomics Research.

**Conference Organization and Invited presentations**

**Conference organization (most relevant in the last 10 years)**

2009 Member of Scientific Committee of Congress “ItPA” 4th Annual National Conference, Italy

2011 Member of Scientific Committee of Congress: “La spettrometria di Massa in Lombardia”, Italy

2014-Present Member of Scientific Committee of the biannual MS-Pharmaday, MS-Envy day, MS-Wine day, MS-Peptide day, MS-Food day Congress, Italy

2014-Present Member of Scientific Committee of the Annual National Congress of the Italian Mass Spectrometry Society (Società Chimica Italiana)

2018 Member of Scientific Committee of the International Mass Spectrometry Congress, Florence, Italy

2020-2022 as President of the Mass Spectrometry Italian Division (Divisione Spettrometria di Massa – Società Chimica Italiana): all congresses organised by DSM-SCI (ie. Massa 2020VIP; SCI2021; Massa2022, 3 MS WIneday, 7 MS-Food day, etc

**Competitive Grants**

2009-2013 FIRB - Fondo per gli Investimenti della Ricerca di Base (Decreto Direttoriale 1 dicembre 2006 prot. n. 2689/Ric./2006) Titolo progetto: Rete Nazionale per lo studio della Proteomica Umana (RBRN07BMCT\_011) 1.600.600 euro

2009-2012 Istituto Italiano di Tecnologia (IIT) piano strategico 2009-2011. Progetti SEED:”Isoelectric focusing chip-array for protein profiling of biological samples with MALDI detection”. 230.000 euro

2013-2017 Call: FP7-PEOPLE-2013-ITN; Funding scheme: Initial Training Networks (ITN); Title: Clinical and system –omics for the identification of the MOlecular DEterminants of established Chronic Kidney Disease. 240.837 euro

## Annex 2

2017-2019 AIRC: Application of a proteomic-based thyroid lesions classifier in cytopathology by MALDI-imaging. 217.800 euro

2019-20 Fellowship Gilead: area di interesse Patologie oncoematologiche e per il settore tematico Linfoma diffuso a grandi cellule B, linfoma primitivo del mediastino e linfoma mantellare: biologia, epidemiologia, diagnostica e modelli di gestione clinica dei pazienti. Titolo: MALDI-MS molecular imaging in diffuse large B-cell lymphoma (DLBCL). Gilead € 25.000,00 euro

2019-2022 Regione Lombardia POR FESR 2014-2020. Call HUB Ricerca ed Innovazione: Sviluppo di nuove molecole di seconda generazione per immunoterapia oncologica (ImmunHUB.) 4.167.588,50 euro

Maggio 2020-ottobre 2020 POR 2014-2020 FESR. Misura RICERCA COVID19. Linea 2: Caratterizzazione della risposta immunitaria protettiva in pazienti affetti da COVID-19 e realizzazione di un saggio immuno-diagnostico (CO-IMMUNITY). Grant: about 100.000 euro

Maggio 2021-aprile 2021 Contratto di ricerca Chiesi Farmaceutici SPA: Caratterizzazione proteomica del modello animale di fibrosi polmonare con topi C57BL/6. Grant: 45.000€

Maggio 2021-aprile 2022 ACCORDO DI COLLABORAZIONE SCIENTIFICA Illycaffè S.p.A: caratterizzazione del caffè attraverso tecniche di imaging mediante spettrometria di massa

2021-.. Ricerca Finalizzata Ministero della Salute 2018-2019: Combined genomic and characterization of follicular thyroid lesions: a project to "save thyroid". Grant: 205.000 euro

2020-2024 Regione Lombardia: PROGRAMMA DEGLI INTERVENTI PER LA RIPRESA ECONOMICA: SVILUPPO DI NUOVI ACCORDI DI COLLABORAZIONE CON LE UNIVERSITÀ PER LA RICERCA, L'INNOVAZIONE E IL TRASFERIMENTO TECNOLOGICO. Titolo: NephropaThy – Piattaforma proteomica di diagnostica differenziale avanzata, basata sulla “firma molecolare”, in patologia renale e tiroidea. Contributo Regione Lombardia 1.760.000 euro

2020-2023 MarioNegri Bergamo CONTRATTO PER AFFIDAMENTO DI PRESTAZIONI DI SERVIZIO RELATIVAMENTE A “ESPERIMENTI DI ANALISI PROTEOMICHE MEDIANTE SPETTROMETRIA DI MASSA PER LA CARATTERIZZAZIONE DI PROTEINE WILD-TYPE FHR3-4 E FHR3-1 IBRIDE. Finanziamento 30.000 euro

2022-.. Contratto di ricerca Chiesi Farmaceutici SPA: Analisi di proteomica e di metabolomica di linee cellulari e terreni di coltura da esse derivanti. Grant: 19.000€

### Patents

Brevetto italiano n. 102015000062301 “Metodo per la diagnosi in vitro di patologie tiroidee” di proprietà dell’Università degli Studi di Milano-Bicocca.  
US Patent: 10,534,005 Method for the in vitro diagnosis of thyroid diseases

### Documented International Collaborations

- o Prof. M Wuher LUMC (Nederland)
- o Prof. M Giampa NTNU (Norway)
- o Prof. DA Murue Calgary Univ (Canada)
- o Prof. AA Ornellas Univ Rio de Janeiro (Brasil)
- o Prof. M. Baumann Univ Helsinki (Finland)
- o Prof. Antonia Vlahou BRFA Academy of Athens (Greece)

**Industrial:** Chiesi Farmaceutici; IllyCaffè, Bioseutica

### Track Record

Researcher unique identifier(s): SCOPUS Author ID: 7006449861, [www.researcherid.com/rid/A-7340-2014](http://www.researcherid.com/rid/A-7340-2014); [orcid.org/0000-0002-8663-0374](http://orcid.org/0000-0002-8663-0374)

197 Papers, about 20 Book Chapters,  
H index 34 (Scopus); Citations 4551 (Scopus)

I am a Member of the “Pool of experts in Proteomics” of the President of the Council of Ministers of the Italian Republic and in the last years I was a Member of the “Management Committee” of the following Cost Actions (BIOMEDICINE AND MOLECULAR BIOSCIENCES):

BM0702: European kidney and urine proteomics ([www.eurokup.org](http://www.eurokup.org))

BM1104: Mass Spectrometry Imaging: New Tools for Healthcare Research.

CA16113 CliniMARK: ‘good biomarker practice’ to increase the number of clinically validated biomarkers

PI of one unit of the project: FP7-PEOPLE-2013-ITN; Initial Training Networks (ITN);

Title: Clinical and system –omics for the identification of the MOlecular DEterminants of established Chronic Kidney Disease.

**Selected Publications (in the last 2 years)**

- 1: Capitoli G, Piga I, L'Imperio V, Clerici F, Leni D, Garancini M, Casati G, Galimberti S, Magni F, Pagni F. Cytomolecular Classification of Thyroid Nodules Using Fine-Needle Washes Aspiration Biopsies. *Int J Mol Sci.* 2022 Apr 9;23(8):4156.
- 2: Chinello C, de Haan N, Capitoli G, Trezzi B, Radice A, Pagani L, Criscuolo L, Signorini S, Galimberti S, Sinico RA, Wuhler M, Magni F. Definition of IgG Subclass-Specific Glycopatterns in Idiopathic Membranous Nephropathy: Aberrant IgG Glycoforms in Blood. *Int J Mol Sci.* 2022 Apr 23;23(9):4664.
- 3: Santorelli L, Stella M, Chinello C, Capitoli G, Piga I, Smith A, Grasso A, Grasso M, Bovo G, Magni F. Does the Urinary Proteome Reflect ccRCC Stage and Grade Progression? *Diagnostics (Basel).* 2021 Dec 16;11(12):2369
- 4: Denti V, Mahajneh A, Capitoli G, Clerici F, Piga I, Pagani L, Chinello C, Bolognesi MM, Paglia G, Galimberti S, Magni F, Smith A. Lipidomic Typing of Colorectal Cancer Tissue Containing Tumour-Infiltrating Lymphocytes by MALDI Mass Spectrometry Imaging. *Metabolites.* 2021 Sep 5;11(9):599.
- 5: Denti V, Andersen MK, Smith A, Bofin AM, Nordborg A, Magni F, Moestue SA, Giampà M. Reproducible Lipid Alterations in Patient-Derived Breast Cancer Xenograft FFPE Tissue Identified with MALDI MSI for Pre-Clinical and Clinical Application. *Metabolites.* 2021 Aug 26;11(9):577.
- 6: Re F, Sartore L, Borsani E, Ferroni M, Baratto C, Mahajneh A, Smith A, Dey K, Almici C, Guizzi P, Bernardi S, Faglia G, Magni F, Russo D. Mineralization of 3D Osteogenic Model Based on Gelatin-Dextran Hybrid Hydrogel Scaffold Bioengineered with Mesenchymal Stromal Cells: A Multiparametric Evaluation. *Materials (Basel).* 2021 Jul 9;14(14):3852.
- 7: Smith A, Piga I, Denti V, Chinello C, Magni F. Elaboration Pipeline for the Management of MALDI-MS Imaging Datasets. *Methods Mol Biol.* 2021;2361:129-142. doi: 10.1007/978-1-0716-1641-3\_8. PMID: 34236659.
- 8: Bianchetti A, Chinello C, Guindani M, Braga S, Neva A, Verardi R, Piovani G, Pagani L, Lisignoli G, Magni F, Russo D, Almici C. A Blood Bank Standardized Production of Human Platelet Lysate for Mesenchymal Stromal Cell Expansion: Proteomic Characterization and Biological Effects. *Front Cell Dev Biol.* 2021 May 14;9:650490.
- 9: Piga I, Capitoli G, Clerici F, Mahajneh A, Brambilla V, Smith A, Leni D, L'Imperio V, Galimberti S, Pagni F, Magni F. Ex vivo thyroid fine needle aspirations as an alternative for MALDI-MSI proteomic investigation: intra-patient comparison. *Anal Bioanal Chem.* 2021 Feb;413(5):1259-1266.
- 10: Fontana D, Mauri M, Renso R, Docci M, Crespiatico I, Røst LM, Jang M, Niro A, D'Aliberti D, Massimino L, Bertagna M, Zambrotta G, Bossi M, Citterio S, Crescenzi B, Fanelli F, Cassina V, Corti R, Salerno D, Nardo L, Chinello C, Mantegazza F, Mecucci C, Magni F, Cavaletti G, Bruheim P, Rea D, Larsen S, Gambacorti-Passerini C, Piazza R. ETNK1 mutations induce a mutator phenotype that can be reverted with phosphoethanolamine. *Nat Commun.* 2020 Nov 23;11(1):5938.
- 11: Rossi F, L'Imperio V, Marti HP, Svarstad E, Smith A, Bolognesi MM, Magni F, Pagni F, Pieruzzi F. Proteomics for the study of new biomarkers in Fabry disease: State of the art. *Mol Genet Metab.* 2021 Feb;132(2):86-93

## Annex 2

- 12: Denti V, Piga I, Guarnerio S, Clerici F, Ivanova M, Chinello C, Paglia G, Magni F, Smith A. Antigen Retrieval and Its Effect on the MALDI-MSI of Lipids in Formalin-Fixed Paraffin-Embedded Tissue. *J Am Soc Mass Spectrom.* 2020 Aug 5;31(8):1619-1624.
- 13: Piga I, Capitoli G, Clerici F, Brambilla V, Leni D, Scardilli M, Canini V, Cipriani N, Bono F, Valsecchi MG, Galimberti S, Magni F, Pagni F. Molecular trait of follicular-patterned thyroid neoplasms defined by MALDI-imaging. *Biochim Biophys Acta Proteins Proteom.* 2020 Nov;1868(11):140511.
- 14: Capitoli G, Piga I, Clerici F, Brambilla V, Mahajneh A, Leni D, Garancini M, Pincelli AI, L'Imperio V, Galimberti S, Magni F, Pagni F. Analysis of Hashimoto's thyroiditis on fine needle aspiration samples by MALDI-Imaging. *Biochim Biophys Acta Proteins Proteom.* 2020 Nov;1868(11):140481. doi: 10.1016/j.bbapap.2020.140481. Epub 2020 Jul 6. PMID: 32645440.
- 15: Raimondo F, Chinello C, Porcaro L, Magni F, Pitto M. Urinary Extracellular Vesicles and Salt-Losing Tubulopathies: A Proteomic Approach. *Proteomes.* 2020 May 9;8(2):9.
- 16: Smith A, Iablokov V, Mazza M, Guarnerio S, Denti V, Ivanova M, Stella M, Piga I, Chinello C, Heijs B, van Veelen PA, Benediktsson H, Muruve DA, Magni F. Detecting Proteomic Indicators to Distinguish Diabetic Nephropathy from Hypertensive Nephrosclerosis by Integrating Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry Imaging with High-Mass Accuracy Mass Spectrometry. *Kidney Blood Press Res.* 2020;45(2):233-248.
- 17: Bosisio FM, Antoranz A, van Herck Y, Bolognesi MM, Marcelis L, Chinello C, Wouters J, Magni F, Alexopoulos L, Stas M, Boecxstaens V, Bechter O, Cattoretti G, van den Oord J. Functional heterogeneity of lymphocytic patterns in primary melanoma dissected through single-cell multiplexing. *Elife.* 2020 Feb 14;9:e53008.
- 18: Santorelli L, Capitoli G, Chinello C, Piga I, Clerici F, Denti V, Smith A, Grasso A, Raimondo F, Grasso M, Magni F. In-Depth Mapping of the Urinary N-Glycoproteome: Distinct Signatures of ccRCC-related Progression. *Cancers (Basel).* 2020 Jan 18;12(1):239.
- 19: Ivanova M, Dyadyk O, Ivanov D, Clerici F, Smith A, Magni F. Matrix-assisted laser desorption/ionization mass spectrometry imaging to uncover protein alterations associated with the progression of IgA nephropathy. *Virchows Arch.* 2020 Jun;476(6):903-914.

### Technical skills and competences

Prof. Fulvio Magni is one of the leading experts on mass spectrometry and its applications to biomedical research, not only in Italy but also in the EU and international MS communities, especially in the field of MS-Imaging clinical applications. He has expertise on Clinical Chemistry (Development of Definitive and Reference Method); on Metabolism (Studies of metabolic pathways with stable isotopes in humans) and on Proteomics. He is responsible for the Proteomic Unit of the University of Milano-Bicocca.

Pursuant to Article 13, Act 675/96 (Privacy Law), I hereby agree to the handling of my personal data.

“Le dichiarazioni rese nel presente curriculum sono da ritenersi rilasciate ai sensi degli artt. 46 e 47 del D.P.R. 445/2000”.

